Intelligence · Patent portfolio
United Therapeutics Europe Patents
Full USPTO pharma patent portfolio for United Therapeutics Europe — grant dates, expiration, and drug cross-links.
- Patents
- 3,720
- Expiring ≤24m
- 234
Quick answer
United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months — use filters for patent-cliff planning.
-
US 11911481
Compositions and methods for treating RSV-infections
granted -
US 11912998
Method of treating aging-associated cognitive impairment by reducing CCR3
granted -
US 11904006
Poly(diaminosulfide) particle-based vaccine
granted -
US 11905313
Recombinant RSV G proteins and their use
granted -
US 11904057
Nanoparticle-hydrogel composite for nucleic acid molecule delivery
granted -
US 11897933
Anti-KRAS-G12D T cell receptors
granted -
US 11898207
Methods of isolating neoantigen-specific T cell receptor sequences
granted -
US 11897875
Deuterated Alpha5 subunit-selective negative allosteric modulators of gamma-aminobutyric acid type a receptors as fast acting treatment for depression and mood disorders
granted -
US 11897845
Small molecule inhibitors of lactate dehydrogenase and methods of use thereof
granted -
US 11898166
In vitro generation of thymic organoid from human pluripotent stem cells
granted -
US 11890330
Endolysins active against Bacillus bacteria, pharmaceutical compositions, and methods relating thereto
granted -
US 11890339
Nipah virus immunogens and their use
granted -
US 11890340
Use of epithelial membrane protein 2 [EMP2] targeting agents in treating lung disorders
granted -
US 11891442
Compositions and methods for treating age-related diseases
granted -
US 11884718
Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following ZIKV infection or vaccination
granted -
US 11883431
T-cells modified to overexpress PHF19
granted -
US 11883468
Compositions and methods to suppress tumor growth in bone, prevent cachectic muscle loss, and preserve skeletal integrity
granted -
US 11878004
Method for inhibiting Zika virus infection
granted -
US 11879017
Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
granted -
US 11878998
Prefusion RSV F proteins and their use
granted -
US 11878064
Nanoparticle/peptide method of blocking potassium channels
granted -
US 11872261
Lipoprotein targeting protease inhibitors and uses
granted -
US 11865125
APKC inhibitors and methods of treating a neurodegenerative disease or disorder
granted -
US 11865111
Antiviral drugs targeting the N-terminal domain (NTD) of the coronavirus spike receptor binding domain (RBD)
granted -
US 11865168
Compositions and methods for treating bacterial infections
granted -
US 11865171
Foot-and-mouth disease vaccine
granted -
US 11865172
Materials and methods for respiratory disease control in canines
granted -
US 11857550
Benzathine analogs
granted -
US 11851498
Anti-CD276 antibodies (B7H3)
granted -
US 11850259
Methods of treating viral infections affecting the respiratory tract using topically administered lithium agents
granted -
US 11850236
Method for inhibiting Zika virus infection
granted -
US 11844779
PKC-Delta-I inhibitor formulations and uses thereof
granted -
US 11845778
Prefusion PIV F immunogens and their use
granted -
US 11844769
Use of cysteamine and derivatives thereof to suppress tumor metastases
granted -
US 11839596
Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
granted -
US 11839631
Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
granted -
US 11839649
Compositions comprising recombinant probiotic bacteria and methods of use thereof
granted -
US 11840561
Anti-KRAS-G12D T cell receptors
granted -
US 11833199
Peptide fragments from filoviruses and their uses
granted -
US 11834509
Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
granted -
US 11833171
Materials and methods relating to stabilised polymeric silicate compositions
granted -
US 11827690
ApoC-II mimetic peptides
granted -
US 11826328
Stable treprostinil prodrugs
granted -
US 11826327
Treatment for interstitial lung disease
granted -
US 11813485
Systems and methods for histotripsy immunosensitization
granted -
US 11814440
Glypican 2 as a cancer marker and therapeutic target
granted -
US 11813316
Lentiviral vector for treating hemoglobin disorders
granted -
US 11813320
Genetically engineered foot and mouth disease virus and related proteins, polynucleotides, compositions, methods and systems
granted
Frequently asked questions
How many patents does United Therapeutics Europe have?
3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do United Therapeutics Europe patents expire?
234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory